Literature DB >> 21062670

Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials.

Toshi A Furukawa1, Tatsuo Akechi, Stefan Wagenpfeil, Stefan Leucht.   

Abstract

BACKGROUND: In randomized controlled trials of antipsychotics, various cutoffs have been used to define response on continuous outcome measures. AIMS: To find a summary effect measure that remains constant across different definitions of response.
METHOD: We conducted secondary analyses of individual patient data from 10 randomized controlled trials of second-generation antipsychotics for schizophrenia (n=4278) by applying a meta-analytic approach to produce odds ratios (OR), risk ratios (RR) and risk differences (RD) and their 95% confidence intervals (CI) for different definitions of response, using cutoffs of 10% through 90% reduction on the symptom severity rating scales. Constancy of these indices was examined through visual inspection, by way of I-squared statistics to quantify heterogeneity, and by way of coefficients of variation. If any of these indices were found to remain reasonably constant, we next examined the concordance between the number needed to treat (NNT) predicted from them and the observed NNT.
RESULTS: OR and RR remained reasonably constant across various definitions of response, especially for those using thresholds of 10% through 70% reduction. The NNTs predicted from OR and RR agreed well with the observed NNTs, with ANOVA intraclass correlation coefficients of 0.96 (95% CI: 0.92 to 0.98) and 0.86 (0.72 to 0.93), respectively.
CONCLUSIONS: The relative measures of treatment effectiveness remain reasonably constant across different scale-derived definitions of response and, in conjunction with varying control event rates, can give accurate estimates of NNTs for individuals with schizophrenia.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21062670     DOI: 10.1016/j.schres.2010.10.016

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  6 in total

1.  Evidence-based Shared-Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia.

Authors:  Stefan Leucht; Johannes Hamann; Spyridon Siafis; Nicola Bursch; Katharina Müller; Lisa Schmid; Florian Schuster; Jakob Waibel; Tri Huynh; Florian Matthes; Alessandro Rodolico; Peter Brieger; Markus Bühner; Stephan Heres
Journal:  BMC Psychiatry       Date:  2022-06-17       Impact factor: 4.144

2.  Practising evidence-based medicine in an era of high placebo response: number needed to treat reconsidered.

Authors:  Steven P Roose; Bret R Rutherford; Melanie M Wall; Michael E Thase
Journal:  Br J Psychiatry       Date:  2016-05       Impact factor: 9.319

3.  How to obtain NNT from Cohen's d: comparison of two methods.

Authors:  Toshi A Furukawa; Stefan Leucht
Journal:  PLoS One       Date:  2011-04-27       Impact factor: 3.240

4.  Antidepressants plus benzodiazepines for adults with major depression.

Authors:  Yusuke Ogawa; Nozomi Takeshima; Yu Hayasaka; Aran Tajika; Norio Watanabe; David Streiner; Toshi A Furukawa
Journal:  Cochrane Database Syst Rev       Date:  2019-06-03

Review 5.  Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia.

Authors:  Myrto T Samara; Elisabeth Klupp; Bartosz Helfer; Philipp H Rothe; Johannes Schneider-Thoma; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2018-05-11

Review 6.  Increasing antipsychotic dose for non response in schizophrenia.

Authors:  Myrto T Samara; Elisabeth Klupp; Bartosz Helfer; Philipp H Rothe; Johannes Schneider-Thoma; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2018-05-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.